Please login to the form below

Not currently logged in
Email:
Password:

NSCLC

This page shows the latest NSCLC news and features for those working in and with pharma, biotech and healthcare.

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

This includes unresectable, stage three non-small cell lung cancer (NSCLC) after chemoradiation therapy and previously-treated advanced bladder cancer. ... Last year, Imfinzi added almost $1.5bn to AZ’s top-line, mainly due to the drug's use as a

Latest news

More from news
Approximately 132 fully matching, plus 384 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Tagrisso’s growth as it moves earlier in the treatment pathway for EGFR-positive non-small lung cancer (NSCLC) and launches in new markets like China, plus possible label extensions for ... checkpoint inhibitor Imfinzi such as the POSEIDON trial in

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    impact of Opdivo plus Yervoy on OS in first-line NSCLC patients’.

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    2019. The only drug that has any realistic chance of challenging Keytruda in NSCLC is Roche’s Tecentriq. ... The Tecentriq chemo trial, IMpower132, is the most important head-to-head with Keytruda (in non-squamous NSCLC).

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    On one hand, it has scored a major success this year by gaining US and EU approval as a monotherapy maintenance treatment for NSCLC patients with inoperable stage 3 disease, ie ... However, recent overall survival results from the MYSTIC trial, which

More from intelligence
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Employee engagement
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals
Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....

Infographics